The Star Medical Supplies - Our Products

Each packet contains 3 grams of sodium phenylbutyrate and 1 gram of taurursodiol. The typical starting dose is 1 packet mixed with 8 oz (or 1 cup) of water once daily for 3 weeks. The mixture is taken by mouth or through a feeding tube.Relyvrio (sodium phenylbutyrate and taurursodiol) is an oral treatment approved in the U.S. and Canada to help slow disease progression in adults with amyotrophic lateral sclerosis (ALS).Patients treated with RELYVRIO experienced a slower rate of decline on a clinical assessment of daily functioning compared to patients receiving a placebo. Additionally, it was observed that some patients who originally received RELYVRIO lived longer when compared to those who originally received placebo.

this medication is used to treat certain cancers (such as chronic lymphocytic leukemia/small lymphocytic lymphoma, waldenstrom's macroglobulinemia). ibrutinib belongs to a class of drugs known as kinase inhibitors. it works by slowing or stopping the growth of cancer cellsibrutinib is used to treat chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll), chronic lymphocytic leukemia (cll)/small lymphocytic leukemia (sll) in patients with 17p deletion, and waldenstrm macroglobulinemia (wm).

ORKAMBI is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who have two copies of the F508del mutation (F508del/F508del) in their CFTR gene. ORKAMBI should not be used in patients other than those who have two copies of the F508del mutation in their CFTR geneOrkambi is a medicine used to treat cystic fibrosis in patients aged 1 year and above. Cystic fibrosis is an inherited disease that has severe effects on the lungs, the digestive system (gut) and other organs

Lucentis is a drug used to treat wet age-related macular degeneration (AMD). It is also used to treat diabetic eye disease and other problems of the retina. It is injected into the eye to help slow vision loss from these diseases. Lucentis is the brand name for the drug, which is called ranibizumab.Ranibizumab is a medication used to manage and treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, myopic choroidal neovascularization, and diabetic retinopathy.LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL LUCENTIS solution) is recommended to be initially administered by intravitreal injection once a month

Humatrope is a man-made form of human growth hormone. It was first approved in 1987 to treat children who are growing slowly because they do not make enough growth hormone on their own. Humatrope is available in 6 mg, 12 mg, and 24 mg cartridges for use in a HumatroPen injection device.

HUMATROPE is also used in adults who do not produce enough natural growth hormone. In adults, HUMATROPE helps to decrease body fat, in growth hormone deficient adults only. Your doctor may have prescribed HUMATROPE for another reason.

Stanozolol is a man-made steroid, similar to the a naturally occurring steroid testosterone. Stanozolol is used in the treatment of hereditary angioedema, which causes episodes of swelling of the face, extremities, genitals, bowel wall, and throat. Stanozolol may decrease the frequency and severity of these attacks

Stanozolol is commonly used by athletes and bodybuilders alike to lose fat while retaining lean body mass. It is usually used in a cutting cycle, to help preserve lean body mass while metabolizing adipose, although it has not been proven conclusively that it has any special fat-burning properties.

Ponatinib is used to treat certain types of chronic myeloid leukemia (CML; a type of cancer of the white blood cells), including treatment in people who can no longer benefit from other medications for CML or who cannot take these medications because of side effects.

ICLUSIG can cause serious side effects, including: Blood clots or blockage in your blood vessels (arteries and veins). Blood clots or blockage in your blood vessels may lead to heart attack, stroke, or death.

OPDIVO (nivolumab) (nivolumab) is a prescription medicine used to treat adults with a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working.

The researchers found that 60% of patients remained recurrence-free after 5 years. They also found that 80% were still alive after 5 years significantly more than typical 5-year survival rates of 36- 68%.